November Newsletter
Golden Helix End-of-Year Bundles 2020

Golden Helix End-of-Year Bundles 2020
By Will Kenworthy 
Sales & Marketing Associate

It’s that time of year again! Golden Helix End-of-Year bundles have been released. We are currently offering our industry-leading products in special bundles for you to simplify and accelerate your current workflows. Whether analyzing and classifying variants, detecting large copy number variant events, or automating your workflow, our software bundles have options for your pipeline from secondary analysis to clinical reporting...

Read More

2020/21 Abstract Competition

2020/21 Abstract Competition
By Dana Odenbeck
Sales & Marketing Associate

Golden Helix strives to enable precision medicine by developing powerful software to support researchers and clinicians with complex analyses. One of my favorite events of the year is our abstract competition. This competition allows us to help our community by recognizing innovative ways to conduct genomic analysis. I am pleased to announce that our 2020/21 Abstract Competition is coming up...

Read More

Evaluating CNVs with VSClinical’s New ACMG Guidelines

Evaluating CNVs with VSClinical’s New ACMG Guidelines
By Eli Sward, Ph.D
Field Application Scientist Manager

In our previous webcast, Evaluating CNVs with VSClinical’s New ACMG Guidelines, we focused on a CNV deletion (12:27715515-29628122×1) in which the patient had a known disorder called Brachydactyly type E. The CNV was isolated using our VS-CNV caller and applied to the ACMG CNV guidelines using the intuitive steps of VSClinical.…

Read More

CEO Corner
Andreas Scherer, PhD
We have officially released our End of Year Software Bundles! You can see all we are offering and what remains here. We hope these packages and our remote assistance program provides some relief for labs across the globe during these difficult times. In addition, we are getting ready for our annual Abstract Competition starting in December. This event is a company favorite for learning about the innovative ways our users are conducting their genomic analysis. I encourage all Golden Helix software users to enter, full details here. Stay tuned for my upcoming announcement detailing all that is in store for Golden Helix in 2021. Until then, I hope you remain safe and healthy and have a wonderful holiday season. Cheers!
Upcoming Webcast

Exploring New Features and Clinical Reports in the ACMG Guideline Workflow
December 2, 2020 | 12:00 PM EST

For the past year, Golden Helix has been preparing a VarSeq release that includes ACMG Guidelines scoring and classification for not only single nucleotide variants but also copy number variants. In the past few months, our webcasts have introduced these guidelines and explored example CNVs that demonstrated the automated scoring of CNVs according to the new ACMG CNV Guidelines. However, there are many other new features and upgrades that have been incorporated into this VarSeq release. These upgrades have largely been driven by input from VarSeq users! That’s why I am very excited to explore these features together in the upcoming webcast “Exploring New Features and Clinical Reports in the ACMG Guideline Workflow”. In this webcast, we will walk through a workflow with SNVs and CNVs highlighting many of the new features and upgrades that will improve and streamline your ACMG workflow. Notably, we will see how these new features can also be incorporated into clinical reports.

Register

About Golden Helix

Golden Helix has been delivering industry-leading bioinformatics solutions for the advancement of life science research and translational medicine for over 20 years with 1,000s of users around the world. Their innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from NGS sequencers and microarrays. With their solutions, hundreds of the world's top hospitals, testing labs, pharmaceutical, biotech, and academic research organizations can harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine.